LearnGlossaryMarketStocksSuperinvestorsSign in

MDWD

MediWound Ltd.

Healthcare · $178M market cap

Verdict

We can't put a fair value on MDWD right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.

Business quality

1 of 5 clear the 10% bar. What are the Big Five?

Earnings per share growth—?
Equity per share growth-0.3% a year✗
Sales growth27.1% a year✓
Free cash flow growth—?
Return on invested capital-36.8%✗

Follow MDWD

Track it on your watchlist and see the full analysis. Free.

Create a free account

Insider activity

Since Sep 1, 2026: 1 open-market purchase worth $7K and 1 sale worth $7K. Why purchases matter

Purchases

Rubinstein Samuel

director · 2026-09-01

Bought

$7K

Sales

Rubinstein Samuel

director · 2026-09-01

Sold

$7K

About MediWound Ltd.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals…

Biotechnology

Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works